Development records
Updates are framed around what has been registered, published, or formally communicated, rather than speculation about what may happen next.
About the resource
About
Still Threshold 82 exists to make complex development information easier to locate, compare, and hold in proportion.
Cairn Grove is an independent resource on ibogaine and noribogaine clinical development, regulatory progress, and safety questions. It helps people distinguish investigational research from unverified treatment claims.
Why this exists
Useful context should not require a leap of faith.
Still Threshold 82 is made for patients, families, researchers, policymakers, and others who need plain language around an unsettled field. Its purpose is not to promote a treatment or predict an outcome, but to make the record easier to inspect.
The work is arranged so that visitors can move from the broader clinical development context to specific questions without treating an early signal as a settled conclusion. Where practical, the resource points toward the underlying record and states what remains uncertain.
Our editorial approach
Follow the record, then name the limits.
Information is assembled from trial registries, peer-reviewed literature, official materials, and public regulatory sources. Trial registration is a useful starting point because the ClinicalTrials.gov registry documents study records and status information that can be checked directly.
We separate reported findings from interpretation, and we avoid filling gaps with certainty. That approach reflects a basic expectation of transparent evidence assessment, including the principles described in the CONSORT reporting guidance for randomized trials.
Our practical tools are collected under the resource’s working guides, with each format intended to help a reader keep source material, status language, and unanswered questions in view.
What we cover
Organized for questions that deserve room.
The resource covers development progress, regulatory context, and safety questions in an organized, general-reference format. It does not stand in for professional judgment, individual screening, or treatment planning.
Plain-language orientation
Definitions are kept close to the questions readers bring, including a careful definition of ibogaine and distinctions between investigational language and promotional claims.
Safety context
Risk information is handled with restraint and is not a substitute for care; readers looking for background on supervised ibogaine settings are encouraged to examine claims with the same care.
Who this is for
A reference point, not a recommendation.
This is for people trying to understand a moving body of information without being asked to accept more than the evidence can support. For example, a question about how long ibogaine effects may last benefits from separating broad background material from an individual medical decision.
Readers can also encounter adjacent public-interest projects, such as ibogaine and ALS discussion or pilot-oriented ibogaine information, while still checking whether the source identifies its evidence, limits, and purpose.
For terminology around formulations, an ibogaine hydrochloride guide may be useful as background, but no external resource should be taken as individualized medical or legal advice.
“Independence means leaving room for a finding to be preliminary, a record to be incomplete, and a reader to decide what questions still need asking.”
Independent by design
Principles kept close to the work.
- Independence before influence.
- Evidence before claims.
- Safety context without false reassurance.
- Plain language without oversimplifying uncertainty.
- Clear limits on what this resource can provide.
Still Threshold 82 is an independent information resource. It is not a clinic, medical provider, licensed treatment center, or legal authority, and its content is not medical or legal advice.